Roles of Programmed Cell Death-1/Programmed Cell Death-ligand 1 and Cytotoxic T-lymphocyte-associated Protein 4 Signaling Pathways in Bladder Urothelial Carcinoma.
10.3881/j.issn.1000-503X.11442
- Author:
Xian Zhi LIN
1
;
Feng Jiang CHEN
1
;
Yong GUO
2
Author Information
1. The First Clinical Medical College of Zhejiang Chinese Medical University,Hangzhou 310053,China.
2. Department of Oncology,the First Affiliated Hospital of Zhejiang ChineseMedical University,Hangzhou 310006,China.
- Publication Type:Journal Article
- Keywords:
bladder urothelial carcinoma;
cytotoxic T-lymphocyte-associated protein 4;
programmed cell death-1/programmed cell death-ligand 1
- MeSH:
Apoptosis;
B7-H1 Antigen;
CTLA-4 Antigen;
Immunotherapy;
Programmed Cell Death 1 Receptor;
Signal Transduction
- From:
Acta Academiae Medicinae Sinicae
2019;41(6):857-865
- CountryChina
- Language:Chinese
-
Abstract:
Bladder urothelial carcinoma(BUC)is a common malignant tumor in the urinary system.Pt-based chemotherapy has long been a standard therapeutic method for resectable or metastatic BUC,but with poor outcomes.Immune checkpoint inhibitors specific to programmed death 1(PD-1)/programmed death-ligand 1(PD-L1)and cytotoxic T lymphocyte-associated protein 4(CTLA-4)pathways have shown significant antitumor activities,safety,and enduring reactivity in clinical trials,thus creating a new epoch for the treatment of advanced-stage BUC.This article reviews the relationships of BUC with PD-1/PD-L1 and CTLA-4 pathways,as demonstrated in clinical trials.In particular,the authors elucidate the clinical studies on the application of immune checkpoint inhibitors in different BUC stages and their optimal combining strategies,with an attempt to improve the clinical use of immune inhibitors for BUC treatment.
